drugset / Trial / NCT02756208
A Safety and Immunogenicity Trial of IHV01
Phase 1
Completed
65 enrolled
University of Maryland, Baltimore
Auro Vaccines LLC · collabBill and Melinda Gates Foundation · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This study is designed to evaluate the safety of the FLSC vaccine and will be a randomized, placebo-controlled, modified double-blinded dose escalation study in 60 healthy adult volunteers (Human Immunodeficiency Virus-1 uninfected).
Timeline
- Start
- 2015-11
- Primary completion
- 2018-07
- Completion
- 2018-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FLSC vaccine | Vaccine | 75 ug | Intramuscular |
| Subject | FLSC vaccine | Vaccine | 150 ug | Intramuscular |
| Subject | FLSC vaccine | Vaccine | 300 ug | Intramuscular |